Interestingly, mast cell–derived IL-2 has been shown to attenuate allergic dermatitis (Hershko et al, 2011), and therapy using IL-2 or its agonist has demonstrated a reduction in clinical symptoms of AD (Hsieh et al, 1991; Silverberg et al, 2024). This evidence concerns the gene IL2 and atopic eczema.